Core Viewpoint - The stock of Yaojie Ankang (02617.HK) experienced significant volatility, closing at 192 HKD with a decline of 53.73%, after reaching a peak of 679.5 HKD, which represented an increase of 63.73% during the trading session [1] Company Overview - Yaojie Ankang is a biopharmaceutical company focused on discovering and developing innovative small molecule therapies for oncology, inflammation, and cardiovascular metabolic diseases, currently in the clinical registration phase [1] IPO Details - Yaojie Ankang was listed on the Hong Kong Stock Exchange on June 23, 2025, with a total of 15,281,000 H-shares offered. The final number of shares for public offering in Hong Kong was 3,057,000 H-shares, while the international offering accounted for 12,224,000 H-shares [1] - The final offering price was set at 13.15 HKD per share, raising a total of 200.95 million HKD. After deducting the estimated listing fees of 39.61 million HKD, the net proceeds amounted to 161.34 million HKD [1]
港股次新股药捷安康股价蹦极 从涨63.7%到跌53.7%